Incyte CORP Form 4 insider transactions

Baker Bros. Advisors and affiliated entities reported the acquisition of Incyte Corp common stock by Julian C. Baker in lieu of director fees, detailing complex beneficial ownership structures.

Incyte Director Paul J. Clancy acquired 285 shares of common stock at $84.81 per share on September 30, 2025, increasing his total beneficial ownership to 23,235 shares.

Incyte Corporation Director Edmund Harrigan acquired 289 shares of common stock valued at $84.81 per share, increasing his beneficial ownership.

Incyte's Chief Strategy Officer, David H. Gardner, received substantial equity awards including restricted stock units, performance shares, and stock options.

Incyte's EVP & General Counsel, Sheila A. Denton, executed a pre-planned transaction, exercising stock options and selling an equal number of shares.

Incyte's EVP & General Counsel, Sheila A. Denton, exercised stock options and immediately sold an equal number of shares under a pre-arranged 10b5-1 plan.

Incyte's EVP of Human Resources, Ramitpal K Basi, was granted restricted stock units, performance shares, and stock options on August 25, 2025.

Incyte's EVP & General Counsel, Sheila A. Denton, exercised stock options and sold a portion of common stock under a pre-arranged 10b5-1 trading plan.

An Incyte executive exercised stock options and immediately sold the acquired shares under a pre-arranged trading plan.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, sold 3,706 shares of common stock at $67.94 per share under a Rule 10b5-1 trading plan.

Incyte Corp's EVP & General Manager US, Barry P Flannelly, sold 1,340 shares of common stock for $68.36 per share under a Rule 10b5-1 trading plan.

Incyte Corp's EVP, Vijay K Iyengar, has filed a Form 4 indicating a future sale of 983 common shares on July 16, 2025, under a pre-arranged Rule 10b5-1 plan.

Incyte Corporation's EVP & General Counsel, Sheila A. Denton, reported multiple transactions including stock option exercises, sales of common stock, and significant new equity awards on July 15 and 16, 2025.

Mohamed Khairie Issa, Incyte Corporation's EVP and Head of US Oncology, was granted a significant equity award package comprising restricted stock units, performance shares, and stock options on July 15, 2025.

Incyte Corporation's EVP and General Manager of US Dermatology, Matteo Trotta, reported new grants of restricted stock units, performance shares, and stock options, alongside a disposition of shares for tax withholding.

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, was granted 6,577 performance shares on July 15, 2025, which can yield up to 200% of common stock based on the company's relative total shareholder return over a three-year period.

Incyte Corp's EVP, Head of Tech. Operations, Michael James Morrissey, was granted 10,961 performance shares, which can yield up to 200% of common stock based on the company's relative total shareholder return over a three-year period.

Incyte Corporation's President of R&D, Pablo J. Cagnoni, has filed a Form 4 detailing future equity awards including restricted stock units, performance shares, and stock options, alongside tax-related share dispositions, all scheduled for mid-July 2025.

Incyte Corporation's EVP & Chief Medical Officer, Steven H. Stein, reported the sale of common stock and the acquisition of new restricted stock units, performance shares, and employee stock options.

Paula J. Swain, Executive Vice President of Human Resources at Incyte Corp, reported the acquisition of new restricted stock units, performance shares, and stock options, alongside the disposition of shares for tax withholding purposes.

Incyte Corporation's EVP & Chief Financial Officer, Christiana Stamoulis, reported the acquisition of substantial restricted stock units, performance shares, and stock options, alongside tax-related dispositions of common stock.

Incyte Corp's Principal Accounting Officer, Thomas Tray, reported the acquisition of restricted stock units and employee stock options, alongside shares withheld for tax obligations.

Incyte Corporation's EVP, Vijay K Iyengar, reported a series of equity transactions including the acquisition of restricted stock units, performance shares, and stock options, alongside routine sales and tax-related dispositions.

An Incyte Corp executive, Barry P. Flannelly, EVP & General Manager US, disposed of 3,255 shares of common stock through pre-planned sales and tax withholdings in mid-July 2025.

Herve Hoppenot, a Director and Special Advisor to the CEO of Incyte Corp, reported the disposition of shares to cover tax withholding obligations related to previously vested equity awards.

Incyte Corp's EVP of Human Resources, Paula J. Swain, reported the disposition of 6,285 common shares at $68.17 per share to cover tax withholding obligations related to previously vested equity.

Incyte Corp's Principal Accounting Officer, Tray Thomas, reported the disposition of 897 shares of common stock to cover tax withholding obligations related to restricted stock units.

Steven H. Stein, Incyte's EVP & Chief Medical Officer, reported a future disposition of 12,714 common shares on July 2, 2025, to cover tax withholding obligations related to equity awards under a Rule 10b5-1 plan.

Incyte Corporation's EVP & Chief Financial Officer, Christiana Stamoulis, reported a routine disposition of 11,589 shares of common stock to satisfy tax withholding obligations related to vested equity, with her beneficial ownership now totaling 117,504 shares.

Barry P Flannelly, EVP & General Manager US of Incyte Corp, reported the withholding of shares for tax obligations and a pre-planned sale of common stock.